ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

ClinicalTrials.gov ID: NCT01143402

Public ClinicalTrials.gov record NCT01143402. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma

Study identification

NCT ID
NCT01143402
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
120 participants

Conditions and interventions

Conditions

Not listed

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2010
Primary completion
Apr 30, 2016
Completion
Apr 30, 2016
Last update posted
Jul 25, 2017

2010 – 2016

United States locations

U.S. sites
3
U.S. states
2
U.S. cities
3
Facility City State ZIP Site status
University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora Colorado 80045
Mount Sinai Medical Center Miami Beach Florida 33140
Moffitt Cancer Center Tampa Florida 33612

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01143402, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 25, 2017 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01143402 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →